在ACPA阴性类风湿性关节炎的临床表现和治疗反应
Baptiste Chevet1, Divi Cornec1
1UMR 1227 Lymphocytes B, Auto-immunité et Immunothérapies, University Brest, Inserm, CHU de Brest, Brest, France.
Joint bone spine
|November 22, 2024
概括
本综述强调了抗氨酸蛋白抗体 (ACPA) 阳性和ACPA 阴性患者之间的类风湿性关节炎 (RA) 呈现和治疗反应的差异. 负ACPA的RA可能呈现出更高的疾病活性,需要个性化治疗策略.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 类风湿性关节炎 (RA) 是一种自身免疫性疾病,具有关节炎症和关节外表现.
- 血清阴性RA (风湿性因子[RF]阴性和ACPA阴性) 越来越多地被认可,需要改进诊断工具.
- 抗素蛋白抗体 (ACPA) 是特定的,但在RA患者中并不普遍存在.
研究的目的:
- 为了比较ACPA阳性与ACPA阴性RA患者的临床表现,诊断挑战和治疗反应.
- 评估新兴生物标志物的实用性,以诊断ACPA阴性RA.
- 强调需要基于ACPA状态的个性化治疗策略.
主要方法:
- 现有文献的综述,比较ACPA阳性和ACPA阴性RA患者队列.
- 对诊断标准,临床特征,放射性结果和治疗疗效的分析.
- 包括新兴生物标志物的数据,如抗PAD4和抗CarP抗体.
主要成果:
- ACPA阴性RA患者经常出现较高的疾病活性,较多的关节胀和CRP水平升高.
- 阳性ACPA患者患关节侵蚀的风险较高,肺部和眼部表现更多.
- 生物药物如阿巴塔塞普和利图西马布在ACPA阳性RA中更有效,而ACPA阴性RA需要仔细重新评估和量身定制的治疗.
结论:
- ACPA状态显著影响RA的表现,进展和治疗反应.
- 新兴的生物标志物有可能改善ACPA阴性RA的诊断.
- 个性化治疗方法对于优化所有RA患者的治疗结果至关重要,特别是那些ACPA阴性患者.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:21Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
7
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
7
01:29Autoimmune Disorders
389
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
389
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142